Running title: Gray et al.; The role of Nox1 in Diabetic Atherosclerosis

Diabetic Complications Division; Human Epigenetics Laboratory; Vascular Pharmacology Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, Australia; Dept of Medicine, Monash University, Melbourne; GenKyoTex SA, Geneva, Switzerland; Ottawa Hospital Research Institute, Ottawa, Canada; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; Dept of Pharmacology & Cardiovascular Research Institute Maastricht (CARIM), Faculty of Medicine, Health & Life Science, Maastricht University, Maastricht, The Netherlands

[1]  M. Kohjima,et al.  Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. , 2015, The Journal of Biological Chemistry.

[2]  D. Brenner,et al.  Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent , 2012, Hepatology.

[3]  S. N. Murthy,et al.  Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. , 2012, American journal of physiology. Heart and circulatory physiology.

[4]  R. Brandes,et al.  Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. , 2012, Free radical biology & medicine.

[5]  H. Schmidt,et al.  NOX4 is a Janus-faced reactive oxygen species generating NADPH oxidase. , 2012, Circulation research.

[6]  A. Manea,et al.  Positive regulation of NADPH oxidase 5 by proinflammatory-related mechanisms in human aortic smooth muscle cells. , 2012, Free radical biology & medicine.

[7]  Min Zhang,et al.  Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase , 2012, Circulation research.

[8]  Merlin C. Thomas,et al.  Distinguishing Hyperglycemic Changes by Set7 in Vascular Endothelial Cells , 2012, Circulation research.

[9]  M. Paul,et al.  NOX1, 2, 4, 5: counting out oxidative stress , 2011, British journal of pharmacology.

[10]  B. Bánfi,et al.  Role for Nox1 NADPH oxidase in atherosclerosis. , 2011, Atherosclerosis.

[11]  R. Touyz,et al.  Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. , 2011, Journal of the American Society of Hypertension : JASH.

[12]  R. Touyz,et al.  NOX isoforms and reactive oxygen species in vascular health. , 2011, Molecular interventions.

[13]  R. Touyz,et al.  Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. , 2011, Clinical science.

[14]  R. Touyz,et al.  Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. , 2010, American journal of physiology. Renal physiology.

[15]  Sophie Houngninou-Molango,et al.  First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. , 2010, Journal of medicinal chemistry.

[16]  H. Schmidt,et al.  Comparative pharmacology of chemically distinct NADPH oxidase inhibitors , 2010, British journal of pharmacology.

[17]  R. Brandes,et al.  NADPH oxidases in cardiovascular disease. , 2010, Free radical biology & medicine.

[18]  H. Schmidt,et al.  Diagnosis and individual treatment of cardiovascular diseases: targeting vascular oxidative stress , 2010, Expert review of clinical pharmacology.

[19]  H. Fuchs,et al.  Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration , 2010, PLoS biology.

[20]  Merlin C. Thomas,et al.  Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor , 2010, Diabetologia.

[21]  K. Krause,et al.  Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 5 (Nox5) Regulation by Angiotensin II and Endothelin-1 Is Mediated via Calcium/Calmodulin-Dependent, Rac-1–Independent Pathways in Human Endothelial Cells , 2010, Circulation research.

[22]  C. Sobey,et al.  Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. , 2010, American journal of physiology. Heart and circulatory physiology.

[23]  K. Kaski,et al.  Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study) , 2009, Cardiovascular diabetology.

[24]  I. Kola,et al.  Site-Specific Antiatherogenic Effect of the Antioxidant Ebselen in the Diabetic Apolipoprotein E–Deficient Mouse , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Lambeth,et al.  Mechanisms of Vascular Smooth Muscle NADPH Oxidase 1 (Nox1) Contribution to Injury-Induced Neointimal Formation , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[26]  G. Mann,et al.  Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. , 2009, Cardiovascular research.

[27]  Merlin C. Thomas,et al.  The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice , 2009, Diabetologia.

[28]  C. McCarthy.  In the Absence of , 2009 .

[29]  M. Hickey,et al.  Pathophysiological Levels of Soluble P-Selectin Mediate Adhesion of Leukocytes to the Endothelium Through Mac-1 Activation , 2008, Circulation research.

[30]  D. Harrison,et al.  Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. , 2008, Free radical biology & medicine.

[31]  K. Bornfeldt,et al.  Diabetes-accelerated atherosclerosis and inflammation. , 2008, Circulation research.

[32]  L. Kennedy.  Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy? , 2008 .

[33]  F. Laurindo,et al.  Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. , 2008, Methods in enzymology.

[34]  Elena Galkina,et al.  Vascular adhesion molecules in atherosclerosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[35]  W. Hsueh,et al.  Recipes for creating animal models of diabetic cardiovascular disease. , 2007, Circulation research.

[36]  J. Falck,et al.  Activation of Vascular Endothelial Growth Factor through Reactive Oxygen Species Mediates 20-Hydroxyeicosatetraenoic Acid-Induced Endothelial Cell Proliferation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[37]  A. Petry,et al.  NOX5 variants are functionally active in endothelial cells. , 2007, Free radical biology & medicine.

[38]  M. Cooper,et al.  Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? , 2007, Endocrinology.

[39]  D. Sorescu,et al.  Nox4 Is Required for Maintenance of the Differentiated Vascular Smooth Muscle Cell Phenotype , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[40]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[41]  K. Krause,et al.  Decreased blood pressure in NOX1‐deficient mice , 2006, FEBS letters.

[42]  H. Abboud,et al.  Nox4 NAD(P)H Oxidase Mediates Hypertrophy and Fibronectin Expression in the Diabetic Kidney* , 2005, Journal of Biological Chemistry.

[43]  D. Weiss,et al.  Nox1 Overexpression Potentiates Angiotensin II-Induced Hypertension and Vascular Smooth Muscle Hypertrophy in Transgenic Mice , 2005, Circulation.

[44]  Masato Matsuki,et al.  Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice , 2005, Circulation.

[45]  U. Walter,et al.  Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. , 2005, Free radical biology & medicine.

[46]  H. Nawata,et al.  NAD(P)H Oxidase Activation: A Potential Target Mechanism for Diabetic Vascular Complications, Progressive β-Cell Dysfunction and Metabolic Syndrome , 2005 .

[47]  M. Cooper,et al.  Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis , 2004, Circulation.

[48]  D. Dunger,et al.  Poor prognosis of young adults with type 1 diabetes: a longitudinal study. , 2003, Diabetes care.

[49]  M. Cooper,et al.  Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.

[50]  E. Schiffrin,et al.  Expression of a Functionally Active gp91phox-Containing Neutrophil-Type NAD(P)H Oxidase in Smooth Muscle Cells From Human Resistance Arteries: Regulation by Angiotensin II , 2002, Circulation research.

[51]  W. R. Taylor,et al.  Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis , 2002, Circulation.

[52]  H. Schmidt,et al.  Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. , 2001, Free radical biology & medicine.

[53]  M. Cybulsky,et al.  A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. , 2001, The Journal of clinical investigation.

[54]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[55]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.